Board of Directors
Stephen J. Fey has a strong background in biomedical science having worked in research universities and companies for the past 30 years. He qualified for his PhD at the Biophysics Department, Kings College, London University, run by Maurice Wilkins (who received the Nobel Prize for his data which led to a description of the structure of DNA). SJF has 114 publications in peer-reviewed scientific journals and has filed 34 different patents (in widely different fields including software for image analysis, equipment for drying gels, producing krill oil, disposables, and diagnostic markers for diabetes, colon cancer, heart rejection) and has given numerous lectures at local, National and International fora. He was the founder of the Centre for Proteome Analysis in 1997 (a new institute at SDU – the world’s first purpose built proteomics institute) and became CEO when the institute was spun out of the SDU to become DrugMode ApS in 2006. DrugMode focussed on three main projects: the early diagnosis of diabetes (years before clinical symptoms become apparent); a novel treatment for diabetes; and 3D cell culture. The early diagnosis project identified a number of potential markers and these have now been successfully handed over to the Diabetes Discovery Platform of the Medical Research Council of South Africa who have the necessary monkey colony and research facilities to take the project further. The novel treatment for diabetes project identified both a herbal remedy and a novel molecule. The herbal remedy is now in clinical trials (run by the mother company of DrugMode ApS) while the novel molecule is being tested for its ability to improve the function of and protect the islets of Langerhans from stress induced destruction. Several leading pharmaceutical companies stated that the 3D cell culture project was too early for them to invest and so in 2010 Stephen J. Fey moved back to the Department of Biochemistry and Molecular Biology at SDU to develop this project further. This work has been the foundation of this business model.
While working as CEO of DrugMode, Stephen J. Fey had to guide the establishment of all the infrastructure necessary for a small company with about 20 employees: (including documentation of activities, introduction of standard operating procedures (SOPs), budgeting, obtaining permission for working with dangerous chemical, narcotics and alcohol, human resources, safety committee, IT, databackup requirements, website (internal and external) and security); acting as scientifically responsible for all projects, problem solver (personnel- as well as project-related); representation of DrugMode at international congresses and conventions, presentations to potential new investors; as well as providing information to the board of directors and the investors and executing the guidelines received from them. He is still a senior scientific advisor to MC2 Biotek and attends all board meetings. Stephen J. Fey is a PRINCE2™ recognised practitioner.
Krzysztof Wrzesinski graduated University of Environmental and Life Sciences Wroclaw, Poland, He pursues his PhD studies at the University of Southern Denmark, Centre for Proteome Analysis, Odense, Denmark establishing human in vitro systems for pre-clinical development of drugs and toxicological assessment of chemical compounds with special emphasis on using different proteomics techniques as downstream analysis methods. As a part of this research he developed methodology for growth and maintenance of 3-dimentional (3D) cell spheroids (tissue like structures). The results were published in the form of a handbook (Wrzesinski, 2009) . After receiving a postdoctoral grant from The Danish Biotechnology Instrument Centre (DABIC) he has been working together with Olympus Denmark A/S on developing new Laser Micromanipulation System specially designed to operate on live 3D tissues and tissue like structures. Part of the prototype systems are now commercialised by Olympus Denmark A/S.
The other part of his research was to investigate the relevance of various fluorescense and luminiscence based technologies for benchmarking of the physiological status of cells grown in 3D tissue like structures.
In 2007 he became part of The Danish National Scientific Expedition – "Galathea 3" participating with professor Peter Roepstorff in the project "Fluorescent proteins; the gift of the oceans to scientific research and biotechnology" where he has collected and analysed over 100 different fluorescent specimens from the coral reefs around the Virgin Islands. The results of this work were presented to the scientific community at several scientific conferences and are published in a peer-reviewed scientific journal.
In 2009 he accepted the position of the "Head of cell and tissue culture laboratory" at DrugMode ApS where he was responsible for production and characterisation of ProtoTissueTM (liver tissue like structures). In 2010 he became a General Manager at DrugMode ApS. He was working on developing not only new methodology but also new types of equipment for improving 3D cell culture systems. He is a co-author of two patents describing significant improvements in 3D spheroid cultures of cells. In 2011 together with Stephen J. Fey, Krzysztof Wrzesinski become cofounder of a new research unit at the Department of Biochemistry and Molecular Biology, University of Southern Denmark (SDU): the Tissue Culture Engineering Laboratory (TCEL group). The group research is focusing on further improvements and detailed physiological characterisation of 3D tissue like structures.
During his scientific carrier he became an expert in: mammalian cell and tissue culture, including microgravity cell culture systems; fluorescent and luminescent cell culture assays; laser microsurgery system; radioisotope and fluorescence protein labelling and visualisation methods; protein separation using two dimensional gel electrophoresis; protein identification and characterisation (including post translational modifications) using mass spectrometry; de novo protein sequencing using mass spectrometry; organelles isolation methods including intact mitochondria, nucleus and cell membrane separations.
He is currently CSO of CelVivo IVS and Associate Professor at the Department of Biochemistry and Molecular Biology in the University of Southern Denmark.
Adelina Rogowska-Wrzesinska is Associate Professor at the University of Southern Denmark, where she and her group focus on biological mass spectrometry and proteomics and its applications in detailed understanding of the dynamics of cellular processes in various biological systems e.g. cells grown in 3D spheroids, myocytes differentiation and during cellular ageing.
As part of her research she has developed large scale methods for studying changes in protein expression and protein post translational modifications, in particular oxidation, phosphorylation and acetylation.
Using nano liquid chromatography coupled with electrospray ion trap - Orbitrap mass spectrometry she has contributed to the in depth characterisation of the physiological changes occurring during the transition of cells growth from 2D to 3D structures and further studied the cellular responses to APAP in cells grown in 3D spheroids.
Adelina Rogowska-Wrzesinska graduated from the University of Wroclaw, Poland and obtained PhD degree in Molecular Biology from University of Southern Denmark. For six years she has worked as project coordinator in a large academic group (Protein Research Group at University of Southern Denmark) carrying out scientific project management, student and postdoc supervision, group and human resources management.
Throughout her carrier she has participated in a number of national and international collaboration projects and networks: Centre for Bioactive Food Components and Prevention of Lifestyle Diseases (MITOHEALTH), Nordic Centre of Excellence Programme on Food, Nutrition and Health; FP7 Marie-Curie Action: Robust affinity materials for applications in proteomics and diagnostics (PEPMIP); New medicines without side effects – Mode of Action by Chemical Proteomics, Danish Agency for Science, Technology and Innovation and European COST action networks CM1001 and BM1203.
Prior to joining Bio Image in 1985, Bob was a principal in a startup which wrote statistical analysis software, and prior to that both a computer programmer and a statistician.
In 1985, Bio Image was a small startup company whose only product was a program to analyze 2D electrophoresis images. During the years since Bob helped Bio Image grow to have a full suite of life science image analysis software, and become the oldest company continuously doing business under the same name.
In 2000 Bob purchased Bio Image from its then-current owners and led an effort to create a 21 CFR Part 11 compliant version of Intelligent Quantifier, Bio Image’s flagship product. The product is used at pharmaceutical plants throughout the world. Bio Image has also provided the image analysis component of high-throughput robots for picking colonies and zebrafish embryos.
Philip Onigman earned a BS in Microbiology at the University of New Hampshire. His first laboratory experiences were at Mass General Hospital, New England Medical Center and Tufts Medical School. Responsibilities included managing primary human amnion cell culture lines, applying human cell lines in viral diagnostic testing, protocol development of media components and contamination control of cell cultures.
At Millipore Corporation, Philip served in Technical Services and Marketing of products for cell culture media sterilization, bioburden, endotoxin and sterility testing, chemotaxis, cytology, first-generation membrane-based bioreactor systems and integrated 2D electrophoresis systems. For biological therapy production facilities, Philip served as worldwide product manager of tangential-flow filtration systems for purification of plasma-derived components such as human albumin, IVIG and Factor VIII, cell-culture production of monoclonal antibodies, polio, DPT and influenza vaccines.
While at GTC Biotherapeutics, Philip supported research initiatives for production of monoclonal antibodies using transgenic systems as an alternative to cell-culture. He served on a team that commercialized Atryn, the first transgenic recombinant therapeutic antithrombin.
As Marketing manager for AdvanDx, Philip led commercialization of first-generation in-situ hybridization tests for rapid direct identification of Staphylococcus aureus and other pathogens from positive blood cultures in hospitals. These proved that rapid ID results could change how antibiotics should be used. The platform enabled reduced antibiotic usage, improved patient survival of sepsis and shorter days of hospitalization.
In 2012, Philip founded Grand Street Consulting, focused on international biotechnology startups introducing new platforms. Technologies supported include research on a new class of antibiotics, LC-MS middle-down analysis of monoclonal antibodies using recombinant enzymes, Antibody Drug Conjugates, MALDI-TOF MS for clinical microbiology, and applications for Adaptive Focused Acoustics.
Background: Educated in electronics and computer science as well as in banking and finance
Experience: (1) Solution architect for banking and finance as well as for AMI (Advanced Measuring Infrastructure); (2) manager of teams of 10-200 persons; (3) previous vice president for ITG SA (now CUBEITG.PL)
Future: Animator and visionary in finding practical solutions
Background: Electronic circuits design
Experience: (1) Practical experience in electronic service; (2) number of professional electronic designs in ITG like Price Checker,
Future: Preparing electronic circuitry in CPLD and FPGA technology for the CelVivo application as well as remote control circuitry and respective software.
Bill is an experienced researcher and leader in the field of high-resolution biological separations and analyses. He has specialized in protein and peptide chemistry, and has expertise in analytical, preparative and process HPLC; 1D and 2D electrophoresis; peptide synthesis and sequencing; and mass spectrometry. In the area of product commercialization, Bill has led teams involved with instrument design, development and manufacture, as well as the development and manufacture of biochemical consumable products.
Bill has extensive experience in moving products through the product development cycle into manufacturing. Former positions include Executive Vice President and General Manager of Proteome Systems, Vice President-Proteomics at Genomic Solutions, Vice President US Operations at Oxford GlycoSystems, Vice President of R&D at PerSeptive BioSystems and Director of Life Science Corporate R&D at Millipore Corporation. Bill has led multidisciplinary groups of scientists and engineers, and has many years experience that include P&L responsibility, strategic and tactical planning, technology licensing, business acquisition, OEM agreements, management of direct and distributor sales, and customer technical and service support.
Background: Fluent in applied mathematics
(doctor in theoretical physics), with good programming practice in
Experience: (1) Managing a 7FR PlugIT project (ontologies and business modelling knowledge transformation) on ITG company side; (2) designed and programed algorithms for filtering images in Aztec code recognition algorithms; (3) big data processing - currently participating in a project on emotional patterns recognition in Twitter messages.
Future: Key person in developing "intelligence" in bioreactors technology